EUCTR2010-023560-40-SE进行中（未招募）不适用
Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study - MIST
ppsala l?ns landsting0 个研究点目标入组 120 人开始时间: 2010年12月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age between 18 -55, inclusive.
- •2. Diagnosis of MS using McDonald criteria of clinically definite MS.
- •3. An EDSS of 2.0 to 6.0.
- •4. Inflammatory disease despite treatment with standard disease modifying therapy including at least 6 months of interferon or copaxone.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Any illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy.
- •2. More than six cycles prior therapy with mitoxantrone.
- •3. Prior history of malignancy except localized basal cell, squameous skin cancer or carcinoma in situ of the cervix. Other malignancies for whoich the patient is judged to be cured, such as haed and neck cancer, or breast cancer wil lbe considered on an individual basis.
- •4. Positive pregnancy test.
- •5. Inability or unwillingness to pursue effective means of birth control....
研究者
相似试验
进行中（未招募）
1 期
Hematopoietic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized StudyInflammatory Multiple SclerosisEUCTR2012-004165-41-GBorthwestern University
招募中
不适用
Hematopoietic stem cell transplantation for patients with ischemic limbsPatients with intractable ulcers caused by collagen diseasesJPRN-UMIN000010799Department of Internal Medicine and Clinical Immunology Yokohama City University Graduate School of Medicine30
尚未招募
1 期
Combined Infusion of Immune Cells and Vaccination to Boost Immunity to Infection After Bone Marrow TransplantatioACTRN12612000800820Professor DJ Gottlieb18
招募中
2 期
Autologous Stem Cell Transplant in Multiple SclerosisNeurological - Multiple sclerosisMultiple SclerosisACTRN12622000536763St Vincent's Hospital, Sydney30
进行中（未招募）
不适用
onmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression with cyclophosfamide administered Before and After Transplantation. A monocentric study. - NDHigh risk Hematologic MalignanciesMedDRA version: 9.1Level: HLGTClassification code 10024324MedDRA version: 9.1Level: HLGTClassification code 10025323EUCTR2009-018083-94-ITISTITUTO EUROPEO DI ONCOLOGIA